Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTFRV98)

• DTT Name: Melanoma antigen gp75 (TYRP1)
• Synonyms: Tyrosinaserelated protein 1; TYRP1; TRP; Glycoprotein 75; Catalase B; 5,6dihydroxyindole2carboxylic acid oxidase
• Gene Name: TYRP1
• DTT Type: Clinical trial target; [1]
• BioChemical Class: Tyrosinase
• UniProt ID: TYRP1_HUMAN
• TTD ID: T00938
• EC Number: EC 1.14.18.-
• Sequence:
  MSAPKLLSLGCIFFPLLLFQQARAQFPRQCATVEALRSGMCCPDLSPVSGPGTDRCGSSS
  GRGRCEAVTADSRPHSPQYPHDGRDDREVWPLRFFNRTCHCNGNFSGHNCGTCRPGWRGA
  ACDQRVLIVRRNLLDLSKEEKNHFVRALDMAKRTTHPLFVIATRRSEEILGPDGNTPQFE
  NISIYNYFVWTHYYSVKKTFLGVGQESFGEVDFSHEGPAFLTWHRYHLLRLEKDMQEMLQ
  EPSFSLPYWNFATGKNVCDICTDDLMGSRSNFDSTLISPNSVFSQWRVVCDSLEDYDTLG
  TLCNSTEDGPIRRNPAGNVARPMVQRLPEPQDVAQCLEVGLFDTPPFYSNSTNSFRNTVE
  GYSDPTGKYDPAVRSLHNLAHLFLNGTGGQTHLSPNDPIFVLLHTFTDAVFDEWLRRYNA
  DISTFPLENAPIGHNRQYNMVPFWPPVTNTEMFVTAPDNLGYTYEIQWPSREFSVPEIIA
  IAVVGALLLVALIFGTASYLIRARRSMDEANQPLLTDQYQCYAEEYEKLQNPNQSVV
• Function: Oxidation of 5,6-dihydroxyindole-2-carboxylic acid (DHICA)into indole-5,6-quinone-2-carboxylic acid. May regulate or influence the type of melanin synthesized.
• KEGG Pathway:
  Tyrosine metabolism (hsa00350)
  Metabolic pathways (hsa01100)
  Melanogenesis (hsa04916)
• Reactome Pathway: Melanin biosynthesis (R-HSA-5662702)

Molecular Interaction Atlas (MIA) of This DTT

2 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
FLX-787	DMQX5UA	Amyotrophic lateral sclerosis	8B60.0	Phase 2	[1]
Flanvotumab	DM2SALJ	Melanoma	2C30	Phase 1	[2]

Molecular Expression Atlas (MEA) of This DTT

Disease Name	ICD 11	Studied Tissue	p-value	Fold-Change	Z-score
Melanoma	2C82	Skin	7.82E-01	0.53	0.21

References

• [1] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [2] National Cancer Institute Drug Dictionary (drug id 675217).